v3.26.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' INVESTMENT - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period $ 2,502,585,166 $ 2,479,417,503 $ 2,487,829,724 [1] $ 2,472,099,655
Issuance of common stock from stock plan transactions (in shares)     1,200,000  
Issuance of common stock from stock plan transactions 1,909,031 1,416,982 $ 4,012,818 6,350,684
Repurchases of common stock (in shares)     (5,900,000)  
Repurchases of common stock (66,020,380) (126,162,931) $ (137,628,305) (202,167,048)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock 9,733,390 7,488,526 20,140,355 16,160,289
Dividends declared (25,283,964) (26,342,490) (50,841,338) (53,321,754)
Capital contributions, net       442,500
Fair value of non-controlling interest in EyeLock LLC   656,000   656,000
Purchase of additional interest in BioCenturion LLC   (3,452,528)   (3,452,528)
Net income (loss) 114,689,417 [2] 95,983,189 [2] 213,144,560 [3] 190,857,234 [3]
Other comprehensive income 488,098 1,633,473 1,442,944 3,012,692
Balance at end of period 2,538,100,758 2,430,637,724 2,538,100,758 2,430,637,724
Parent        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period 2,502,585,166 2,474,826,003 2,487,829,724 2,467,950,655
Issuance of common stock from stock plan transactions 1,909,031 1,416,982 4,012,818 6,350,684
Repurchases of common stock (66,020,380) (126,162,931) (137,628,305) (202,167,048)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock 9,733,390 7,488,526 20,140,355 16,160,289
Dividends declared (25,283,964) (26,342,490) (50,841,338) (53,321,754)
Purchase of additional interest in BioCenturion LLC   1,139,021   1,139,021
Net income (loss) 114,689,417 [2] 96,039,584 [2] 213,144,560 [3] 190,913,629 [3]
Other comprehensive income 488,098 1,633,473 1,442,944 3,012,692
Balance at end of period $ 2,538,100,758 $ 2,430,038,168 $ 2,538,100,758 $ 2,430,038,168
Common Stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period (in shares) 212,979,921 224,817,117 215,445,024 227,207,472
Balance at beginning of period $ 12,778,795 $ 13,489,027 $ 12,926,701 $ 13,632,448
Issuance of common stock from stock plan transactions (in shares) 424,869 405,697 1,212,462 1,115,693
Issuance of common stock from stock plan transactions $ 25,492 $ 24,342 $ 72,748 $ 66,942
Repurchases of common stock (in shares) (2,696,740) (5,702,064) (5,949,436) (8,802,415)
Repurchases of common stock $ (161,804) $ (342,124) $ (356,966) $ (528,145)
Balance at end of period (in shares) 210,708,050 219,520,750 210,708,050 219,520,750
Balance at end of period $ 12,642,483 $ 13,171,245 $ 12,642,483 $ 13,171,245
Additional  Paid-In Capital        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period 1,007,716,711 1,011,756,899 1,008,589,267 1,010,440,420
Issuance of common stock from stock plan transactions 1,883,539 1,392,640 3,940,070 6,283,742
Repurchases of common stock (11,272,373) (22,865,277) (24,608,425) (35,111,663)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock 9,733,390 7,488,526 20,140,355 16,160,289
Purchase of additional interest in BioCenturion LLC   1,139,021   1,139,021
Balance at end of period 1,008,061,267 998,911,809 1,008,061,267 998,911,809
Retained  Earnings        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period 1,480,867,060 1,454,610,199 1,466,046,002 1,450,287,128
Repurchases of common stock (54,586,203) (102,955,530) (112,662,914) (166,527,240)
Dividends declared (25,283,964) (26,342,490) (50,841,338) (53,321,754)
Net income (loss) 114,689,417 [2] 96,039,584 [2] 213,144,560 [3] 190,913,629 [3]
Balance at end of period 1,515,686,310 1,421,351,763 1,515,686,310 1,421,351,763
Accumulated  Other Comprehensive Income (Loss)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period 1,222,600 (5,030,122) 267,754 (6,409,341)
Other comprehensive income 488,098 1,633,473 1,442,944 3,012,692
Balance at end of period 1,710,698 (3,396,649) 1,710,698 (3,396,649)
Equity Attributable to Noncontrolling Interests        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Balance at beginning of period 0 4,591,500 0 4,149,000
Capital contributions, net       442,500
Fair value of non-controlling interest in EyeLock LLC   656,000   656,000
Purchase of additional interest in BioCenturion LLC   (4,591,549)   (4,591,549)
Net income (loss)   (56,395) [2]   (56,395) [3]
Balance at end of period $ 0 $ 599,556 $ 0 $ 599,556
[1] The Condensed Consolidated Balance Sheet at December 31, 2025 has been derived from the audited Consolidated Financial Statements at that date, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.
[2] Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $505,646 and $332,739 for the three months ended June 30, 2026 and 2025, respectively (see Note 16).
[3] Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $539,730 and $332,739 for the six months ended June 30, 2026 and 2025, respectively (see Note 16).